Faslodex Injection
Product Images NDC 0310-0720

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Faslodex (NDC 0310-0720). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure14

Figure14
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
FDA Label Image

Figure 10 (Figure 10)

Figure 10 (Figure 10)
This appears to be a graph or table showing the Overall Survival Probability (%) and the number of patients at risk over a period of 54 months. The comparison is between two groups, one receiving FASLODEX with palbociclib and the other receiving FASLODEX with placebo. The survival times are shown in months from time 0 to 54 months. There is more data in the table, but due to the formatting, does not provide accurate details.*
FDA Label Image

Figure 11

Figure 11
This is a graph that shows the progression-free survival probability (%) for two groups of patients - one group received FASLODEX plus Abemaciclib treatment (N=446) and the other group received FASLODEX plus Placebo (N=223). The survival probability is indicated on the y-axis and the months are indicated on the x-axis. The number of patients at risk is also indicated on the x-axis for each time point.*
FDA Label Image

Figure 12

Figure 12
This is a graph displaying the survival rates of patients who were given FASLODEX plus Abemaciclib versus FASLODEX plus Placebo over a period of 57 months. There were 446 patients in the FASLODEX plus Abemaciclib group and 223 in the FASLODEX plus Placebo group. The y-axis represents the percentage of patients still alive, and the x-axis represents the time in months. The survival rate of the FASLODEX plus Abemaciclib group is consistently higher than the survival rate of the FASLODEX plus Placebo group.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
FDA Label Image

Figure 6

Figure 6
This appears to be a graph or chart showing the progression-free survival over time for patients. The graph displays the terms "Progression Free Survival," "ITT Population," "FASLODEX 250mg," and "FASLODEX 500mg." The x-axis shows time in months, with up to 45 months shown. The y-axis displays values ranging from 0 to 1.0, with increments of 0.1 labeled. There appears to be two lines, one labeled "FASLODEX 250mg," and the other labeled "FASLODEX 500mg," each showing a curve for progression-free survival over time. The graph also displays numbers at risk for each group at different points in time. A more detailed description of the graph cannot be provided based on this limited and incomplete text.*
FDA Label Image

Figure 7

Figure 7
This is a graph showing the proportion of patients who were alive over time while taking either FASLODEX 500mg or FASLODEX 250mg. The time frame is over 80 months and it appears that there is no statistically significant difference between the two doses, but adjustments were not made for multiplicity. The number of patients at risk for each dose at each time point is also shown.*
FDA Label Image

Figure 8

Figure 8
FDA Label Image

Figure 9

Figure 9
This is a clinical study that compares the efficacy of FASLODEX with and without palbociclib in terms of progression-free survival. The text includes a graph that shows the probability of progression-free survival over time for each treatment option. The results suggest that FASLODEX combined with palbociclib has a higher probability of progression-free survival compared to FASLODEX with a placebo.*
FDA Label Image

Ndc0310 0720 10

Ndc0310 0720 10
FDA Label Image

Chemical Structure Faslodex (Chemical Structure Faslodex)

Chemical Structure Faslodex (Chemical Structure Faslodex)
FDA Label Image

Figure12

Figure12
This appears to be a graph showing censoring times for two different treatments (FASLODEX with Ribociclib and FASLODEX with Placebo). The graph shows the percentage of patients still at risk over a period of 26 months, with the number of patients still at risk also displayed. The number of patients still at risk decreases over time for both treatments.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.